Aripiprazole

Pharmacology, efficacy, safety and tolerability

Warren A. Kinghorn, Joseph Patrick McEvoy

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase half-life relative to other antipsychotic medications. Randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. Aripiprazole is generally well tolerated relative to other antipsychotic medications, although commonly reported side effects include worsening extrapyramidal symptoms and motoric activation similar to akathisia. Further studies and postmarketing data will be helpful in providing additional information about the comparative safety, efficacy and tolerability of aripiprazole.

Original languageEnglish (US)
Pages (from-to)297-307
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume5
Issue number3
DOIs
StatePublished - May 1 2005

Fingerprint

Antipsychotic Agents
Pharmacology
Safety
Schizophrenia
Psychomotor Agitation
Bipolar Disorder
Psychotic Disorders
Half-Life
Therapeutics
Placebos
Recurrence
Aripiprazole

Keywords

  • Antipsychotic medication
  • Aripiprazole
  • Bipolar mania
  • Schizoaffective disorder
  • Schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Aripiprazole : Pharmacology, efficacy, safety and tolerability. / Kinghorn, Warren A.; McEvoy, Joseph Patrick.

In: Expert Review of Neurotherapeutics, Vol. 5, No. 3, 01.05.2005, p. 297-307.

Research output: Contribution to journalReview article

@article{f263ea6e8152427cb7db181aee3fa9a7,
title = "Aripiprazole: Pharmacology, efficacy, safety and tolerability",
abstract = "Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase half-life relative to other antipsychotic medications. Randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. Aripiprazole is generally well tolerated relative to other antipsychotic medications, although commonly reported side effects include worsening extrapyramidal symptoms and motoric activation similar to akathisia. Further studies and postmarketing data will be helpful in providing additional information about the comparative safety, efficacy and tolerability of aripiprazole.",
keywords = "Antipsychotic medication, Aripiprazole, Bipolar mania, Schizoaffective disorder, Schizophrenia",
author = "Kinghorn, {Warren A.} and McEvoy, {Joseph Patrick}",
year = "2005",
month = "5",
day = "1",
doi = "10.1586/14737175.5.3.297",
language = "English (US)",
volume = "5",
pages = "297--307",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Aripiprazole

T2 - Pharmacology, efficacy, safety and tolerability

AU - Kinghorn, Warren A.

AU - McEvoy, Joseph Patrick

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase half-life relative to other antipsychotic medications. Randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. Aripiprazole is generally well tolerated relative to other antipsychotic medications, although commonly reported side effects include worsening extrapyramidal symptoms and motoric activation similar to akathisia. Further studies and postmarketing data will be helpful in providing additional information about the comparative safety, efficacy and tolerability of aripiprazole.

AB - Aripiprazole is a recently released antipsychotic medication which differs from other atypical antipsychotic agents by its partial agonist activity at postsynaptic D2 receptors. It is administered orally and is distinguished by a long elimination phase half-life relative to other antipsychotic medications. Randomized studies have demonstrated the efficacy of aripiprazole relative to placebo in the treatment of acute relapse of schizophrenia and schizoaffective disorder, maintenance treatment of schizophrenia, and treatment of acute bipolar mania. Aripiprazole is generally well tolerated relative to other antipsychotic medications, although commonly reported side effects include worsening extrapyramidal symptoms and motoric activation similar to akathisia. Further studies and postmarketing data will be helpful in providing additional information about the comparative safety, efficacy and tolerability of aripiprazole.

KW - Antipsychotic medication

KW - Aripiprazole

KW - Bipolar mania

KW - Schizoaffective disorder

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=18944362633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18944362633&partnerID=8YFLogxK

U2 - 10.1586/14737175.5.3.297

DO - 10.1586/14737175.5.3.297

M3 - Review article

VL - 5

SP - 297

EP - 307

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 3

ER -